FDx Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History

FDx Advisors’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-50,620	Closed	-$275K	–	1157
2018 Q1	$275K	Sell	50,620 -3,069	-6%	-$15.3K	0.01%	1008
2017 Q4	$224K	Buy	53,689 +29,729	+124%	+$179K	0.01%	1155
2017 Q3	$231K	Buy	+23,960	New	+$249K	0.01%	1158

Other funds holding GNMK

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

FDx Advisors's GNMK Position: Q2 2018 in Review

FDx Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2018, closing a stake of 50,620 shares — an estimated $275K sold.

FDx Advisors first reported a position in GNMK in Q3 2017 and held it in 3 quarters. The position peaked at $275K in Q1 2018. 105 funds tracked by Wall St. Rank hold GNMK as of Q2 2018.

FDx Advisors reported no remaining GenMark Diagnostics, Inc position as of Q2 2018 after selling out during the quarter.
FDx Advisors sold 50,620 GenMark Diagnostics, Inc shares in Q2 2018, an estimated $275K.
FDx Advisors first reported a position in GenMark Diagnostics, Inc in Q3 2017 and held it in 3 quarters.
FDx Advisors's GenMark Diagnostics, Inc position peaked at $275K in Q1 2018.
105 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2018.

Based on FDx Advisors's 13F filing for Q2 2018, filed 8 Aug 2018.